$JAGX, I dont think many of YOU have ever read this letter, statement properly. https://jaguarhealth.gcs-web.com/news-releases/news-release-details/preclinical-study-demonstrating-symptomatic-relief-diarrhea-dogs
If you did, you would probably understand how imortant it is.
"The study was conducted by Jaguar subsidiary Napo Pharmaceuticals, Inc. in collaboration with Puma Biotechnology, Inc.
Mytesi is antidiarrheal drug, currently indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS.
Nerlynx, of Puma Biotechnology, Inc, is a pan HER TKI indicated for the extended adjuvant treatment of adult patients with early stage HER2 positive breast cancer and also for metastatic HER2 positive breast cancer.
"A 28-day preclinical pharmacological study in healthy female dogs was conducted without the prophylaxis or concomitant use of loperamide and demonstrated that crofelemer caused an approximate 30% reduction in the incidence and severity of diarrhea associated with daily oral administration of neratinib, which was statistically significant. Crofelemer also demonstrated significant improvement in the proportion of responder dogs, and there was a trend for fewer neratinib dose reductions in both crofelemer treatment groups when compared to the control group."
No dogs in any treatment group during the study received loperamide to reduce the incidence or severity of diarrhea.
Furthermore: Crofelemer is undergoing development for a potential additional indication of symptomatic relief of cancer therapy-related diarrhea (CTD) and in prevention and/or relief of CTD.
Compared to placebo-treated dogs, the average number of watery stools per week was significantly less for both the crofelemer QID and crofelemer BID treatment groups during Week 1 as well as throughout the entire four-week treatment period.
Dogs receiving placebo had an approximately 33% higher average number of watery stools when compared to dogs randomized to the crofelemer BID or QID groups (p < 0.05).
Finally, stool consistency as measured by the average fecal scores per week per neratinib tablet showed significantly more formed stools for the crofelemer QID and BID groups over the entire 28-day treatment period compared to the control group."
Good luck with your investements guys and girls!